Literature DB >> 6249893

Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes.

A G Engel.   

Abstract

Overwhelming evidence now supports Simpson's concept, originally proposed in 1960, that acquired myasthenia gravis (MG) is an autoimmune disease in which antibodies are directed against the nicotine postsynaptic acetylcholine receptor (AChR).1 An autoimmune pathogenesis of acquired MG implies that those myasthenic syndromes which occur in a congenital and familial setting may have a different, non-autoimmune basis. This paper focuses on ultrastructural, immunoelectron microscopic and cytochemical aspects of acquired autoimmune MG and some recently recognised congenital myasthenic syndromes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249893      PMCID: PMC490625          DOI: 10.1136/jnnp.43.7.577

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations.

Authors:  A G Engel; E H Lambert; F M Howard
Journal:  Mayo Clin Proc       Date:  1977-05       Impact factor: 7.616

2.  Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton-Lambert syndrome.

Authors:  J M Lindstrom; E H Lambert
Journal:  Neurology       Date:  1978-02       Impact factor: 9.910

3.  A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release.

Authors:  A G Engel; E H Lambert; M R Gomez
Journal:  Ann Neurol       Date:  1977-04       Impact factor: 10.422

4.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

5.  Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera.

Authors:  S Heinemann; J Merlie; J Lindstrom
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

6.  Antibody to acetylcholine receptor increases degradation of junctional and extrajunctional receptors in adult muscle.

Authors:  C G Reiness; C B Weinberg; Z W Hall
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

7.  Cell membrane antigen isolation with the staphylococcal protein A-antibody adsorbent.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

8.  Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome.

Authors:  A G Engel; T Santa
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

9.  Voltage clamp analysis of acetylcholine produced end-plate current fluctuations at frog neuromuscular junction.

Authors:  C R Anderson; C F Stevens
Journal:  J Physiol       Date:  1973-12       Impact factor: 5.182

10.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

View more
  11 in total

1.  Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.

Authors:  Grace M McMacken; Sally Spendiff; Roger G Whittaker; Emily O'Connor; Rachel M Howarth; Veronika Boczonadi; Rita Horvath; Clarke R Slater; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

2.  Immunoadsorption therapy for myasthenia gravis.

Authors:  N Shibuya; T Sato; M Osame; T Takegami; S Doi; S Kawanami
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

3.  Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis.

Authors:  H N Willcox; J Newsom-Davis; L R Calder
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

4.  Congenital myopathy with myasthenic features and congenital cataract in two siblings.

Authors:  Y Nishida; T Kobayashi; M Machi; T Yamada; T Kitaguchi; K Oda; I Goto
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

5.  The ocular signs and symptoms of myasthenia gravis.

Authors:  H J Oosterhuis
Journal:  Doc Ophthalmol       Date:  1982-01-29       Impact factor: 2.379

6.  Cell surface complement regulators moderate experimental myasthenia gravis pathology.

Authors:  Linda L Kusner; Jose A Halperin; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2012-10-05       Impact factor: 3.217

Review 7.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  Paucity of secondary synaptic clefts in a case of congenital myasthenia with multiple contractures: ultrastructural morphology of a developmental disorder.

Authors:  L M Smit; F G Jennekens; H Veldman; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

9.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12

10.  Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.

Authors:  H Link; O Olsson; J Sun; W Z Wang; G Andersson; H P Ekre; T Brenner; O Abramsky; T Olsson
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.